Intranasal WSK-IM05 Vaccine Plus Tislelizumab as Neoadjuvant Therapy for HPV+ OPSCC

计划入组 9 人 · 首次发布于 2026 年 5 月 4 日

Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC

计划入组 334 人 · 首次发布于 2013 年 6 月 10 日

P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC

计划入组 195 人 · 首次发布于 2017 年 3 月 10 日

HPV-X

HPV CD40 HVac

SQZ-PBMC-HPV

Merck & Co Inc

United States

HAV Vaccines Limited

United Kingdom

Worcester HIV Vaccine

United States

Naveris Showcases NavDx Test Advances for HPV-Associated Oropharyngeal Cancer Surveillance at ASTRO 2024

De-escalated Radiation Therapy Reduces Toxicity While Maintaining Cure Rates in HPV-Positive Oropharyngeal Cancer

BioAtla Secures $40 Million Funding to Advance Ozuriftamab Vedotin into Phase 3 Trial for Oropharyngeal Cancer